320 related articles for article (PubMed ID: 25466965)
21. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of T-LAK cell-originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma.
Wei DC; Yeh YC; Hung JJ; Chou TY; Wu YC; Lu PJ; Cheng HC; Hsu YL; Kuo YL; Chen KY; Lai JM
Cancer Sci; 2012 Apr; 103(4):731-8. PubMed ID: 22192142
[TBL] [Abstract][Full Text] [Related]
23. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase.
Dougherty JD; Garcia AD; Nakano I; Livingstone M; Norris B; Polakiewicz R; Wexler EM; Sofroniew MV; Kornblum HI; Geschwind DH
J Neurosci; 2005 Nov; 25(46):10773-85. PubMed ID: 16291951
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of mutant p53 protein expression in lung adenocarcinoma].
Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
Zhongguo Fei Ai Za Zhi; 2015 Jan; 18(1):23-8. PubMed ID: 25603869
[TBL] [Abstract][Full Text] [Related]
25. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer.
Park JH; Lin ML; Nishidate T; Nakamura Y; Katagiri T
Cancer Res; 2006 Sep; 66(18):9186-95. PubMed ID: 16982762
[TBL] [Abstract][Full Text] [Related]
26. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase (PBK/TOPK) in Patients with Cancer.
Zhang Y; Yang X; Wang R; Zhang X
J Cancer; 2019; 10(1):131-137. PubMed ID: 30662533
[No Abstract] [Full Text] [Related]
28. Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
World J Surg Oncol; 2015 Mar; 13():128. PubMed ID: 25890228
[TBL] [Abstract][Full Text] [Related]
29. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
30. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis.
Gao T; Hu Q; Hu X; Lei Q; Feng Z; Yu X; Peng C; Song X; He H; Xu Y; Zuo W; Zeng J; Liu Z; Yu L
Cancer Lett; 2019 Mar; 445():11-23. PubMed ID: 30590102
[TBL] [Abstract][Full Text] [Related]
31. The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis.
Zykova TA; Zhu F; Wang L; Li H; Bai R; Lim DY; Yao K; Bode AM; Dong Z
EBioMedicine; 2017 Apr; 18():73-82. PubMed ID: 28412249
[TBL] [Abstract][Full Text] [Related]
32. The Protective Role of the TOPK/PBK Pathway in Myocardial Ischemia/Reperfusion and H₂O₂-Induced Injury in H9C2 Cardiomyocytes.
Sun G; Ye N; Dai D; Chen Y; Li C; Sun Y
Int J Mol Sci; 2016 Feb; 17(3):267. PubMed ID: 26907268
[TBL] [Abstract][Full Text] [Related]
33. PBK/TOPK expression during TPA-induced HL-60 leukemic cell differentiation.
Liu YH; Gao XM; Ge FM; Wang Z; Wang WQ; Li XY
Asian Pac J Cancer Prev; 2012; 13(5):2145-8. PubMed ID: 22901184
[TBL] [Abstract][Full Text] [Related]
34. miR-216b promotes cell growth and enhances chemosensitivity of colorectal cancer by suppressing PDZ-binding kinase.
Zou J; Kuang W; Hu J; Rao H
Biochem Biophys Res Commun; 2017 Jun; 488(2):247-252. PubMed ID: 28373071
[TBL] [Abstract][Full Text] [Related]
35. [Correlation between expression of long non-coding RNA ZXF1 and prognosis of lung adenocarcinoma and its potential molecular mechanism].
Pan GF; Zhou XF; Zhao JP
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):102-108. PubMed ID: 28219204
[No Abstract] [Full Text] [Related]
36. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
37. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
Guo T; Zhao S; Li Z; Li F; Li J; Gu C
Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
[TBL] [Abstract][Full Text] [Related]
38. PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.
Brown-Clay JD; Shenoy DN; Timofeeva O; Kallakury BV; Nandi AK; Banerjee PP
Oncotarget; 2015 Jun; 6(17):15594-609. PubMed ID: 25909225
[TBL] [Abstract][Full Text] [Related]
39. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
Li Y; Yang Z; Li W; Xu S; Wang T; Wang T; Niu M; Zhang S; Jia L; Li S
Oncotarget; 2016 Feb; 7(6):6748-64. PubMed ID: 26745678
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of MAGEA2 has a prognostic significance and is a potential therapeutic target for patients with lung cancer.
Ujiie H; Kato T; Lee D; Hu HP; Fujino K; Kaji M; Kaga K; Matsui Y; Yasufuku K
Int J Oncol; 2017 Jun; 50(6):2154-2170. PubMed ID: 28498455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
